NE-ADJUVANCE-TECH
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,906,926. The patent is directed to triterpene saponin analogues, specifically Adjuvance’s next generation saponin adjuvant TQL-1055, which exhibits improved adjuvant activity and reduced toxicity as compared to QS-21.
U.S. Patent No. 10,906,926 protects the TQL-1055 composition of matter, pharmaceutical compositions incorporating TQL-1055, methods of using TQL-1055 for immunization against infections, and methods for obtaining TQL-1055. The patent includes 21 claims and follows issuance of similar patents in certain other countries around the world.
The patent has been assigned to Adjuvance and Memorial Sloan Kettering Cancer Center (New York, USA), where advanced synthetic saponin technology was first developed. Adjuvance exclusively licensed MSK’s foundational technology in 2011 and has since continued to innovate. Adjuvance seeks to apply TQL-1055 in improved vaccine compositions, including an improved shingles vaccine expected to enter clinical development during 2022. Adjuvance will continue to develop its vaccine adjuvant technology by creating, developing, and manufacturing a family of next-generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships.
MSK Disclosure : Memorial Sloan Kettering Cancer Center (MSK) has intellectual property rights and associated financial interests related to Adjuvance Technologies by virtue of licensing agreements between MSK and Adjuvance Technologies.
About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant, which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically-advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS-21 and has shown favorable tolerability in a Phase 1 clinical trial. Adjuvance is designing new combination adjuvants, with TQL-1055 as the foundation, to produce different types of immune responses.
About Shingles : Shingles (also known as herpes zoster) is a painful rash that develops, often on the face or torso, and has the potential complication of pain that can last for months or even years. Vaccination against shingles is recommended in the United States and many countries for older adults and people with weak immune systems, resulting in a market value of over $2.0 billion in 2020. Available shingles vaccines contain the saponin adjuvant QS-21 and the toll-like receptor (TLR) 4 agonist adjuvant monophosphoryl lipid A (MPL), known together as the AS01 adjuvant. The adjuvanted shingles vaccine is highly effective, but can cause short-term adverse events more intense than other vaccines. About 1 out of 6 people who got the available shingles vaccine experienced side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days.
About Adjuvance Technologies : Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our lead vaccine candidate against shingles aims to provide a better patient experience including improved tolerability for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institutes of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005083/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MUSASHI JAPAN Launches “Gift Campaign 2025” - A Holiday Tradition Honoring Craftsmanship Through Meaningful Gifts2.12.2025 15:07:00 CET | Press release
MUSASHI JAPAN by TAIMATSU announces the return of its year-end celebration, Gift Campaign 2025, a seasonal tradition that transforms holiday shopping into an experience of appreciation, craftsmanship, and cultural generosity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202812444/en/ Rather than focusing on discounts, MUSASHI embraces the philosophy that true value lies in tools that last and in the gestures that accompany them. This year’s campaign invites customers to discover gifts that enrich their craft in the kitchen, each thoughtfully chosen to support the longevity and performance of every Musashi blade. Inspired by the Japanese principle of omotenashi, the campaign offers customers tiered gifts based on their total purchase amount, ensuring that every contribution is met with gratitude and purpose. From December 2 to December 25, 2025, customers shopping in MUSASHI JAPAN stores will receive: Tier 1: Oil and Rus
Invisible IT Emerges as Workplace Transformation Evolves, Lenovo Research Finds2.12.2025 15:00:00 CET | Press release
Four out of five IT leaders say their systems can’t keep up and are turning to AI-powered automation to make IT seamless, predictive, and proactive. The next step in workplace transformation is invisible technology that fades into the background so that support is automated and seamless, according to a Lenovo global survey of IT leaders released today. Most employees only notice IT when it slows them down and interrupts processes. Invisible IT is the opposite. It means technology that anticipates needs, prevents issues before they happen, and personalizes support automatically. Achieving Invisible IT, the newest report in Lenovo’s ongoing Work Reborn series, explores how AI and automation are redefining the digital workplace and employee experience. Of the IT leaders who participated, 79% aspire to deliver seamless, proactive support that minimizes disruption for employees, but only 21% have achieved predictive issue resolution. The results underscore an urgent need for organizations t
Wasabi Launches Covert Copy, a Completely Invisible and Indestructible Copy of Data for a Higher Level of Cloud Storage Security2.12.2025 15:00:00 CET | Press release
Key takeaways:A patent pending innovation in data protection that affords the best protection yet from ransomwareEnables account managers to create a hidden, immutable copy of data that is invisible to anyone inside the corporate networkSupports wide range of compliance requirements across all industries Wasabi Technologies, the hot cloud storage company, has expanded its cyber resilient cloud storage capabilities with Covert Copy, a patent pending, advanced ransomware-resistant storage solution that allows users to create a locked, hidden copy of storage buckets to ensure critical data remains untouchable, even in the event of a cyberattack. The selected data is logically air gapped and cannot be seen, accessed, modified or deleted, without multi-user authentication approval, protecting it from any type of malicious attack. Covert Copy strengthens and simplifies traditional air gap strategies by creating a copy of data that is not only isolated, but unable to be detected at all. As th
Incode Launches Deepsight, the World’s Most Accurate Deepfake Defense2.12.2025 15:00:00 CET | Press release
Validated by Purdue University, this breakthrough AI system protects enterprises from deepfakes, synthetic identities, and AI-generated fraud at scale Incode Technologies, the global leader in identity security and fraud prevention, today announced the launch of Deepsight, a breakthrough AI defense that detects and blocks deepfakes, injected virtual cameras, and synthetic identity attacks with unmatched accuracy. When Identity Can Be Faked, Everything Breaks As AI systems increasingly interact and transact autonomously, the ability to instantaneously separate real people from AI-generated fakes becomes critical. Deepsight’s multi-modal AI analyzes video, motion, and depth data to expose inconsistencies that synthetic media cannot reproduce, all in under 100 milliseconds and without adding friction. “Deepfakes have evolved beyond novelty. They are now a major fraud weapon,” said Ricardo Amper, Founder and CEO of Incode. “When identity can be faked, everything breaks. Deepsight restores
Xsolla Advances Global Gaming Education and Innovation in Collaboration With HP2.12.2025 15:00:00 CET | Press release
New Initiative Connects HP’s Gaming Garage and Xsolla’s Accelerator Program to Create a Global Ecosystem for Learning, Development, and Entrepreneurship Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, today announced a strategic relationship with HP to connect education, technology, and entrepreneurship across the global games industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202381208/en/ Rytis Joseph Jan, SVP Global Strategic Initiatives & Partnerships at Xsolla The collaboration combines HP’s Gaming Garage learning platform with Xsolla’s Accelerator to create an end-to-end ecosystem that enables aspiring creators to learn, build, and launch their own studios. The integration acts as a catalyst for global opportunities for innovation, introducing new models for game education, incubation, and professional development on a large scale. The program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom